Clinical trials: Sexual Arousal Disorder
Vulvovaginal Signs and Symptoms, Genitourinary Syndrome of Menopause
Effects of Ospemifene on Brain Activation Patterns in Women With Sexual Interest-arousal Disorders
Ospemifene is the first oral and non-hormonal treatment for moderate or severe vulvo-vaginal atrophy (VVA) in postmenopausal women who are not candidates to treatment with local oestrogens.
- Conditions
- Vulvovaginal Signs and Symptoms, Genitourinary Syndrome of Menopause, Sexual; Disorder, Arousal, Female
- Trial name
- EROS (NCT04677491)
- Testing
- Ospemifene 60 mg, fMRI experiments
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Hospital Clinic of Barcelona
Female Sexual Arousal Disorder
Alprostadil (FemLife Gel) in the Treatment of Female Sexual Arousal Disorder
Female sexual arousal disorder (FSAD) is a frequent finding in women in middle age and more prevalent in post-menopausal women. Topical alprostadil is currently under development for the treatment of FSAD.
- Trial name
- NCT00572377
- Testing
- FemLife Gel
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center